NCT06619873已完成1 期
A Phase 1, Open-Label, Single-Dose, Randomized, Four-Period Crossover Study to Evaluate the Relative Bioavailability and Food Effect of HRS-8080 in Healthy Subjects
Shandong Suncadia Medicine Co., Ltd.1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2024年10月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
The study is being conducted to evaluate the relative bioavailability of HRS-8080 in the fasted state in healthy adult subjects and to assess the impact of food on HRS-8080 PK for the Phase 3 capsule in healthy adult.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial;
- •Between 18 and 45 years of age, inclusive;
- •Female subjects with weight ≥ 45kg, male subjects with weight ≥50kg, body mass index (BMI) range 19 to 26 kg/m2, inclusive at Screening;
- •Subjects of childbearing potential must agree to take contraceptive measures, and use requested contraceptive measures with their partners from signing the ICF to 6 months after the last dose. Female subjects must have a negative serum pregnancy test within 7 days prior to the first dose, be non-lactating, and agree to avoid egg donation during the treatment period until 6 months after the last dose of the investigational drug.
排除标准
- •Having a significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), neurological, or psychiatric disorder (as determined by the Investigator);
- •Having a history of epilepsy, including childhood febrile seizures, loss of consciousness, transient ischemic attack or any condition that may cause seizures, such as cerebrovascular disease, brain injury, stroke or brain cancer, etc.;
- •History of severe infection within the past 30 days, including but not limited to bacteremia, severe sepsis, pneumonia requiring hospitalization;
- •History of stomach or intestinal surgery (including cholecystectomy) or resection that would potentially alter absorption and/or excretion of orally administered drugs except that appendectomy and hernia repair will be allowed;
- •Clinically significant findings from medical history, 12-lead ECG, or vital signs;
- •GFR < 90 ml/min/1.73 m2;
- •Having a QTc interval >470 msec for female and >450 msec for male;
- •Positive hepatitis panel (hepatitis B surface antigen and hepatitis C virus antibody) or human immunodeficiency virus (HIV) antibody screens;
- •Having a history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator; History of allergy to HRS-8080 or any of its excipients;
- •The use or intent to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including prescription medication, over the counter medication and traditional Chinese medication, within 30 days prior to screening;
- •The participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 half-lives or 30 days, whichever is longer, prior to screening;
- •Participated in blood donation within 3 months before screening and donated ≥ 400 mL of blood or ≥ 400 mL of blood loss; Participated in blood donation within 1 month before screening and donated blood volume ≥ 200 mL or blood loss ≥ 200 mL; Those who have received blood transfusions or used blood products within 3 months before screening;
- •Positive test for selected drugs of abuse at Screening;
- •The use of drugs of abuse (including opioids) within3 months of Screening;
- •having a history of alcoholism or heavy smoker within 3 month prior screening; unable to abstain from smoking or alcohol during the trial period;
- •Poor peripheral venous access;
- •The need to follow a special diet and unable to consume the high-fat meal;
- •Pregnant or Breastfeeding;
- •In the opinion of the Investigator or Sponsor, are unsuitable for inclusion in the study.
研究组 & 干预措施
Medication regimen C-B-D-A
Experimental
干预措施: HRS-8080 (Drug)
Medication regimen B-A-C-D
Experimental
干预措施: HRS-8080 (Drug)
Medication regimen A-D-B-C
Experimental
干预措施: HRS-8080 (Drug)
Medication regimen D-C-A-B
Experimental
干预措施: HRS-8080 (Drug)
结局指标
主要结局
Cmax
时间窗: 0 hour-48 hour
AUC0-t
时间窗: 0 hour-48 hour
AUC0-inf
时间窗: 0 hour-48 hour
次要结局
- Tmax(0 hour-48 hour)
- T1/2(0 hour-48 hour)
- CL/F(0 hour-48 hour)
- Vz/F(0 hour-48 hour)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Relative Bioavailability Food Effect Study of LY03005Major Depressive DisorderNCT03822065Luye Pharma Group Ltd.34
已完成
1 期
A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male PatientsHealthy Male ParticipantsNCT01707342Janssen R&D Ireland6
已完成
1 期
A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and TabletsEndometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted ReproductionNCT05868057Jiangsu HengRui Medicine Co., Ltd.16
已完成
1 期
A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015KBioavailability of ASP015KPharmacokinetics of ASP015KHealthy SubjectsNCT01486017Astellas Pharma Inc30
已完成
1 期
Phase 1, Febuxostat XR Relative Bioavailability StudyHealthy VolunteersNCT02504320Takeda78